XPO1 and neoplasm: Additionally, XPO1 blockade reduces the translation of short-lived immune-suppressive proteins (e.g., PD-L1) and perturbs stress-adaptation circuits that drive immune checkpoint upregulation—effects that synergize with BH3 mimetics (venetoclax) and HMAs (azacitidine) to enhance anti-tumor immunity (Glaviano et al., 2025).